Related Experiment Video
Updated: Aug 12, 2026
07:20
Inducement and Evaluation of a Murine Model of Experimental Myopia
Published on: January 22, 2019
Low-Concentration Atropine for Myopia Management: Recent Evidence and Clinical Implications
Imran Jawaid1,2, Carla Lanca3,4
1Moorfields Eye Hospital, Dubai, United Arab Emirates. Imran.jawaid@moorfields.ae.
Ophthalmology and Therapy
|August 11, 2026
Summary
Low-concentration atropine effectively manages myopia, but efficacy varies by age, ethnicity, and dosage. Further research is needed for optimal strategies and rebound progression management.
Area of Science:
- Ophthalmology
- Clinical Trials
- Myopia Management
Background:
- Myopia is a growing global health concern.
- Low-concentration atropine is investigated for myopia control.
- Understanding atropine efficacy requires analyzing diverse trial data.
Purpose of the Study:
- To review randomized controlled trials (RCTs) on low-concentration atropine for myopia.
- To compare atropine efficacy across different populations and dosages.
- To identify factors influencing treatment outcomes and future research directions.
Main Methods:
- Conducted a narrative review of peer-reviewed RCTs.
- Searched databases using "myopia" and "atropine" terms.
- Extracted and compared data on refractive error, axial length, and demographics.
Main Results:
- Early trials (ATOM, LAMP) in Asian populations showed dose-dependent efficacy (0.05% > 0.01%).
- Recent studies (STAR, MOSAIC, WA-ATOM, MTS) in non-Asian populations reported modest effects for 0.01% atropine.
- Efficacy influenced by age, ethnicity, baseline progression, environment, and COVID-19.
Conclusions:
- Low-concentration atropine is promising but has variable efficacy.
- Rebound progression after cessation is a concern.
- Future research should explore higher concentrations, individualized treatments, and normative growth comparisons.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...